There has been extensive progress in understanding the cellular and molecular
mechanisms of inflammation and immune regulation in allergic diseases of the skin and …

Patients with severe uncontrolled asthma have disproportionally high morbidity and
healthcare utilization as compared with their peers with well-controlled disease. Although …

Novel therapies such as type 2 targeting biologics are emerging treatment options for
patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely …

Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …

Introduction Thymic stromal lymphopoietin (TSLP), an epithelial cytokine (alarmin), is a
central regulator of the immune response to inhaled environmental insults such as …

Background Stepwise intensification of inhaled corticosteroids (ICS) is routine for severe
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …

Importance Structural racism has been implicated in the disproportionally high asthma
morbidity experienced by children living in disadvantaged, urban neighborhoods. Current …

Background Patients with severe, uncontrolled asthma have a significant unmet need for
new treatments that have broader effects on airway inflammation, and that provide greater …

Inflammation, structural, and functional abnormalities within the airways are key features of
asthma. Although these processes are well documented, their expression varies across the …

Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled
asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric …